Article

Arzerra Fails in Phase 3 Trial for B-cell Lymphoma

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

GlaxoSmithKline/Genmab's leukaemia drug ofatumumab (marketed as Arzerra) has hit a setback after failing to meet targets in a late-stage trial assessing its potential in patients with B-cell lymphoma.

GSK said it is now unlikely that ofatumumab will be filed for this indication, given that a combination of the drug plus chemotherapy failed to outperform a rituxan/chemotherapy combo on progression free survival in patients with relapsed/refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma (NHL).

Read the report here: http://bit.ly/1j5bSXD

Source: PharmaTimes online

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Related Content
FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi
The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
June 7th 2025

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

Jared Kaltwasser
The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com
June 6th 2025

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

Rose McNulty
Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.
young adult cancer | Image credit: Roswell Park Cancer Center
June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey
Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo